STAT+: Doctors are more tied to pharma as trust erodes
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning. Today, we read about a big acquisition fueled by obesity, doctors shifting their views on biopharma marketing, see a rare disease drug win approval after a long stretch of uncertainty, and more.
Pfizer to acquire Metsera, developer of obesity drugs
Pfizer is paying $47.50 a share in cash for Metsera, a 43% premium on the startup’s closing price on Friday that gives the deal an enterprise value of $4.9 billion. The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulatory milestones for Metsera’s medicines.
Meghana Keshavan
Go to statnews